Isoface may be available in the countries listed below.
Isotretinoin is reported as an ingredient of Isoface in the following countries:
International Drug Name Search
Active Ingredients: Cupric Sulfate, Zinc Sulfate, Citric Acid [Powder for use in solution]
Directions: It is recommended for use in a 1% to 3% solution strength (by weight) with immersion lasting between 5 and 20 minutes, once or twice daily, for a period of time as prescribed by your veterinarian.
Warnings:
Keep out of reach of children.
Purpose:Copper Mate powder is used as an aid in hoof rot management under veterinary guidance.
Use:Copper Mate powder is used in hoof baths for cattle and sheep.
When Using this Product: By placing a clean water bath ahead of the treatment bath, animals will clean their hooves to some extent and keep the treatment bath clean longer. Hoof baths should only be part of an overall program that includes proper nutrition, regular hoof trimming, and hoof injury prevention.
Questions?: 1-800-567-7455 (24/7-Emergency Spill Line) or 1-905-878-8432
| Copper Mate acidified cupric and zinc sulfate powder, for solution | ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| unapproved drug other | 12/15/2010 | ||
| Labeler - Fondel Chemical Ltd. (201786790) |
| Registrant - Fondel Chemical Ltd. (201786790) |
| Establishment | |||
| Name | Address | ID/FEI | Operations |
| Fondel Chemical Ltd. | 201786790 | manufacture, label | |
Relieving symptoms of sinus congestion, pressure, runny nose, and sneezing due to colds, upper respiratory infections, and allergies. It may also be used for other conditions as determined by your doctor.
Phena-S Liquid is an antihistamine and decongestant combination. The antihistamine works by blocking the action of histamine, which helps reduce symptoms such as watery eyes and sneezing. The decongestant promotes sinus and nasal drainage, which relieves congestion and pressure.
Contact your doctor or health care provider right away if any of these apply to you.
Some medical conditions may interact with Phena-S Liquid. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with Phena-S Liquid. Tell your health care provider if you are taking any other medicines, especially any of the following:
This may not be a complete list of all interactions that may occur. Ask your health care provider if Phena-S Liquid may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use Phena-S Liquid as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Phena-S Liquid.
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Constipation; diarrhea; dizziness; drowsiness; excitability; headache; loss of appetite; nausea; nervousness or anxiety; trouble sleeping; upset stomach; vomiting; weakness.
Severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); difficulty urinating or inability to urinate; fast or irregular heartbeat; hallucinations; seizures; severe dizziness, lightheadedness, or headache; tremor; trouble sleeping; vision changes.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
See also: Phena-S side effects (in more detail)
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include blurred vision; confusion; hallucinations; seizures; severe dizziness, lightheadedness, or headache; severe drowsiness; unusually fast, slow, or irregular heartbeat; vomiting.
Store Phena-S Liquid at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Phena-S Liquid out of the reach of children and away from pets.
This information is a summary only. It does not contain all information about Phena-S Liquid. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
Class: Sulfonylureas
ATC Class: A10BB05
VA Class: HS502
Chemical Name: 1-(Hexahydro-1-H-azepin-1-yl)-3-(p)-tolylsulfonyl) urea
CAS Number: 1156-19-0
Antidiabetic agent; sulfonylurea.a b
Monotherapy as an adjunct to diet and exercise for the management of type 2 (noninsulin-dependent) diabetes mellitus in patients whose hyperglycemia cannot be controlled by diet and exercise alone.a b
Second-line therapy in combination with one or more other oral antidiabetic agents or insulin as an adjunct to diet and exercise in patients with type 2 diabetes mellitus who do not achieve adequate glycemic control with diet, exercise, and oral antidiabetic agent monotherapy. 136 146 147 148 149 150 166 167 169 170 171 172 173 174 175 176
Alternative therapy in some type 2 diabetic patients being treated with insulin or other antidiabetic agent(s) or unresponsive to other sulfonylureas.a Useful in combination with insulin to improve glycemic control and/or decrease insulin dosage in some type 2 diabetic patients.136 146 147 151 152 154 155 156 157 158 159
Not effective as sole therapy for patients with type 1 diabetes mellitus101 103 106 132 b or diabetic acidosis, ketosis, or coma; insulin is necessary.101 102 106 a b (See Contraindications under Cautions.)
Not routinely recommended in hospitalized patients with diabetes mellitus.119 Long duration of action precludes rapid dosage adjustments.119 132 Increased risk of hypoglycemia in hospitalized diabetic patients with irregular eating patterns.119
Adjust dosage according to severity of disease, tolerance, and blood glucose determinations.b
Monitor regularly (e.g., blood glucose concentrations) to determine minimum effective dosage and to detect primary or secondary failure.119 a b
Monitor glycosylated hemoglobin (HbA1c) to determine patient’s continued response to therapy.119
During transfer from insulin therapy, patients should test their blood glucose concentrations ≥3 times daily.a b
Administer orally as a single dose with breakfast or first main meal; for dosages >500 mg daily, administer in 2 divided doses.a b
Initially, 100–250 mg daily.a b
Manufacturer suggests that, if the fasting blood glucose is <200 mg/dL, initially, 100 mg daily; if fasting blood glucose >200 mg/dL, initially, 250 mg daily.a b
May discontinue most other oral antidiabetic agents abruptly.a b
Acetohexamide: Initially, 100 mg daily for each 250 mg daily of acetohexamide.a b
Chlorpropamide: Administer the nearest equivalent total daily dosage; however, an exaggerated hypoglycemic response may occur in some patients during the transition because of the prolonged elimination half-life of chlorpropamide.a b Monitor closely for hypoglycemia during the initial 1- to 2-week transition period.a b
Tolbutamide: Tolbutamide dosages ≤1 g daily, initially 100 mg daily.b Tolbutamide dosage >1 g daily, initially, 250 mg daily.a b
Insulin requirements <20 units daily: Initially, 100 mg daily.a b May abruptly discontinue insulin.a
Insulin requirements 20–40 units of insulin daily: Initially, 250 mg daily.a b May abruptly discontinue insulin.a
Insulin requirements >40 units daily: Initially, 250 mg daily; reduce daily insulin dosage by 50%.a b Subsequently, adjust insulin dosage according to therapeutic response.a b
Titrate dosage according to patient's response, using lowest possible effective dosage.a b Adjust dosage in increments or decrements of 100–250 mg daily at weekly intervals.a b
Usual maintenance dosage is 100 mg to 1 g daily (average 250–500 mg daily).a b Patients not responding to 1 g daily are unlikely to respond to higher dosages.a b
Maximum 1 g daily.a b
Use conservative initial and maintenance dosages to avoid hypoglycemia.a b
Use conservative initial and maintenance dosages to avoid hypoglycemia.a b
Initially, 100 mg daily.a b May increase dosage by 50–125 mg daily at weekly intervals.a Use conservative initial and maintenance dosages to avoid hypoglycemia.a b
Initially, 100 mg daily.a b May increase dosage by 50–125 mg daily at weekly intervals.a Use conservative initial and maintenance dosages to avoid hypoglycemia.a b
Known hypersensitivity to tolazamide.b
Monotherapy for type 1 diabetes mellitus.a b
Diabetic ketoacidosis, with or without coma.a b
Acute complications (e.g., major surgery, severe infection, or severe trauma).a
Uremia.a
Increased cardiovascular mortality reported with certain other antidiabetic agents (i.e., tolbutamide, phenformin).106 108 109 112 125 129 130 131 b However, the American Diabetes Association (ADA) considers the benefits of intensive glycemic control with insulin or sulfonylureas to outweigh the risks overall.109 119 125
Possible allergic skin reaction (e.g., pruritus, erythema, urticaria, rash, morbilliform or maculopapular eruptions).a b May be transient; discontinue the drug if reaction persists.b
Rarely, photosensitivity reactions reported.a b
Possibly severe hypoglycemia reported, especially in debilitated, malnourished, or geriatric patients and patients with adrenal, pituitary, hepatic, or renal insufficiency.a b Strenuous exercise, alcohol ingestion, insufficient caloric intake, or use in combination with other antidiabetic agents may increase risk.a b
Hypoglycemia may be difficult to recognize in geriatric patients and in those receiving β-adrenergic blocking agents.b (See Specific Drugs under Interactions.)
Increased risk of hypoglycemia in patients with irregular eating patterns.119
Appropriate patient selection and careful dosing and instructions are important to avoid tolazamide-induced hypoglycemia.a b
If hypoglycemia occurs, immediately reevaluate patient and adjust insulin or tolazamide dosage.a Monitor patient for ≥24–48 hours; may require hospitalization and IV dextrose.b
Possible loss of glycemic control during periods of stress (e.g., fever, trauma, infection, surgery).a b May require use of insulin and/or temporary discontinuance of tolazamide.a b
Efficacy of therapy may decrease over time (secondary failure); evaluate patients at regular intervals.a b
Assess patients for adequate adjustment of dose and adherence to diet before attributing inadequate response to secondary failure.b
Manufacturer recommends discontinuance of tolazamide if satisfactory glycemic control no longer is achieved.b ADA and other clinicians recommend addition of other oral antidiabetic agents or insulin.124 147 179 180 181 182 183 186 188 (See Diabetes Mellitus under Uses.)
Cholestatic jaundice and alterations in liver function test results (e.g., bilirubin, cholesterol, AST, ALT) reported.a b If cholestatic jaundice occurs, discontinue the drug.b
Use with caution in patients with a history of hepatic porphyria; sulfonylureas may exacerbate this condition.a b
Category C.b
Many experts recommend the use of insulin during pregnancy.b
Not recommended for use during pregnancy by manufacturer.b Prolonged (4–10 days), severe hypoglycemia reported in some neonates born to women receiving a sulfonylurea at delivery; more frequent with long-acting sulfonylureas.b If used during pregnancy, discontinue ≥2 weeks before the expected delivery date to minimize the risk of neonatal hypoglycemia.b
Not known whether tolazamide is distributed into human milk.b Some sulfonylurea drugs are distributed into human milk.b Discontinue nursing or the drug.b
If drug is discontinued and diet alone is inadequate for glycemic control, consider insulin.b
Safety and efficacy not established.b
Increased risk of hypoglycemia;a b hypoglycemia may be difficult to recognize.b
Possible increased risk of hypoglycemia due to age-related decreases in renal function.b Renal function monitoring recommended; select dosage with caution.a b
Increased risk of hypoglycemia; conservative dosing recommended.a b
Increased risk of hypoglycemia; conservative dosing recommended.b (See Renal Impairment under Special Populations in Dosage and Administration.)
Nausea,a b epigastric fullness,b heartburn,b vomiting,a anorexia,a intestinal gas,a diarrhea,a constipation,a cramps.a
Potential pharmacokinetic interaction (increased hypoglycemic effect).b (See Specific Drugs under Interactions.)
Close observation recommended when initiating or discontinuing concomitant therapy with a highly protein-bound drug.b
Drug | Interaction | Comments |
|---|---|---|
Alcohol | Possible disulfiram-like reactionsa May predispose patients to the development of hypoglycemiab | |
Anticoagulants, oral | Possible potentiation of hypoglycemic effectsb | Observe carefully for hypoglycemia or loss of glycemic control when concurrent therapy is initiated or discontinuedb |
Antifungals, oral (i.e., fluconazole, miconazole) | Increased plasma concentrations of the oral antidiabetic agent and/or possible hypoglycemia167 b | Not known whether interaction occurs with IV, topical, or vaginal miconazoleb Observe carefully for hypoglycemia or loss of glycemic control when concurrent therapy is initiated or discontinuedb |
β-Adrenergic blocking agents | Possible potentiation of hypoglycemic effectsb Signs of hypoglycemia may be masked by β-adrenergic blocking agentsb | Observe carefully for hypoglycemia or loss of glycemic control when concurrent therapy is initiated or discontinuedb |
Calcium-channel blocking agents | Potential for decreased hypoglycemic effectb | Observe carefully for hypoglycemia or loss of glycemic control when concurrent therapy is initiated or discontinuedb |
Chloramphenicol | Possible potentiation of hypoglycemic effectsb | Observe carefully for hypoglycemia or loss of glycemic control when concurrent therapy is initiated or discontinuedb |
Contraceptives, oral | Potential for decreased hypoglycemic effectb | Observe carefully for hypoglycemia or loss of glycemic control when concurrent therapy is initiated or discontinuedb |
Corticosteroids | Potential for decreased hypoglycemic effectb | Observe carefully for hypoglycemia or loss of glycemic control when concurrent therapy is initiated or discontinuedb |
Diuretics | Potential for decreased hypoglycemic effecta b May cause temporary loss of diabetic control or secondary failurea | Observe carefully for hypoglycemia or loss of glycemic control when concurrent therapy is initiated or discontinueda b |
Estrogens | Potential for decreased hypoglycemic effectb | Observe carefully for hypoglycemia or loss of glycemic control when concurrent therapy is initiated or discontinuedb |
Insulin | Possible potentiation of hypoglycemic effectsa | Observe carefully for hypoglycemia or loss of glycemic control when concurrent therapy is initiated or discontinuedb |
Isoniazid | Potential for decreased hypoglycemic effectb | Observe carefully for hypoglycemia or loss of glycemic control when concurrent therapy is initiated or discontinuedb |
MAO inhibitors | Possible potentiation of hypoglycemic effectsa b | Observe carefully for hypoglycemia or loss of glycemic control when concurrent therapy is initiated or discontinuedb |
Niacin | Potential for decreased hypoglycemic effectb | Observe carefully for hypoglycemia or loss of glycemic control or when concurrent therapy is initiated or discontinuedb |
NSAIAs | Possible potentiation of hypoglycemic effectsb | Observe carefully for hypoglycemia or loss of glycemic control when concurrent therapy is initiated or discontinuedb |
Phenothiazines | Potential for decreased hypoglycemic effectb | Observe carefully for hypoglycemia or loss of glycemic control when concurrent therapy is initiated or discontinuedb |
Phenytoin | Potential for decreased hypoglycemic effectb | Observe carefully for hypoglycemia or loss of glycemic control when concurrent therapy is initiated or discontinuedb |
Probenecid | Possible potentiation of hypoglycemic effectsa b | Observe carefully for hypoglycemia or loss of glycemic control when concurrent therapy is initiated or discontinuedb |
Salicylates | Possible potentiation of hypoglycemic effectsa b | Observe carefully for hypoglycemia or loss of glycemic control when concurrent therapy is initiated or discontinuedb |
Sulfonamides | Possible potentiation of hypoglycemic effectsa b | Observe carefully for hypoglycemia or loss of glycemic control when concurrent therapy is initiated or discontinuedb |
Sympathomimetic agents | Potential for decreased hypoglycemic effectb | Observe carefully for hypoglycemia or loss of glycemic control when concurrent therapy is initiated or discontinuedb |
Thyroid agents | Potential for decreased hypoglycemic effectb | Observe carefully for hypoglycemia or loss of glycemic control when concurrent therapy is initiated or discontinuedb |
Rapidly and well absorbed following oral administration.b Peak serum concentrations attained at 3–4 hours.b
Following a single 500 mg dose in nondiabetic, fasting adults, hypoglycemic effect occurs within 20 minutes; peak hypoglycemic effect occurs at 1–4 hours.a b
Following a single 500 mg dose in fasting diabetics, peak hypoglycemic effect occurs at 4–6 hours.b
In nonfasting diabetics, onset of hypoglycemic effect occurs within 4–6 hours.a b
In nondiabetic, fasting adults, pharmacologic effects persist for at least 20 hours.a b
In nonfasting diabetics, hypoglycemic activity persists for about 10 hours; blood glucose concentrations begin to increase at 14–16 hours following a single dose.a b
Distributed into extracellular fluids; distribution not fully characterized.a
Not known whether tolazamide is distributed into milk.b
Metabolized to active and inactive metabolites, probably in the liver.a b
Excreted principally in urine (85%) principally as metabolites and in feces (7%); small amounts excreted in urine unchanged.a b
Approximately 7 hours.a b
Tight, light-resistant containers at 20–25°C.a b Protect from light.b
Mechanism of long-term hypoglycemic action of sulfonylurea antidiabetic agents has not been clearly established.b Appears to lower blood glucose concentration principally by stimulating the secretion of endogenous insulin from the beta cells of the pancreas.a b
Ineffective in the absence of functioning beta cells.a
Lowers blood glucose concentration in diabetic and nondiabetic individuals.a b
During prolonged administration, extrapancreatic effects (e.g., enhanced peripheral sensitivity to insulin, reduction of basal hepatic glucose production) may contribute to the hypoglycemic action.a b
A gradual decline in the insulin secretory response to drug may occur; however, blood glucose lowering effect persists.b
May produce a mild diuresis by enhancement of renal free water clearance.b
Importance of informing patients of potential risks and advantages of tolazamide therapy and of alternative forms of treatment.b
Importance of regular monitoring of blood glucose (preferable self-monitoring) and of HbA1c.b
According to manufacturer, patients should test their urine for glucose and acetone ≥3 times daily during insulin withdrawal.b Report abnormal results to clinician for appropriate adjustments in therapy.b
Importance of hygiene and avoidance of infection.a
Advise patients about nature of diabetes mellitus, prevention and detection of complications, and importance of glycemic control.a
Risks of hypoglycemia.a b Importance of patients and responsible family members understanding symptoms and treatment of hypoglycemic reactions and identifying conditions that predispose to development of such reactions.a b
Importance of understanding primary and secondary failure to therapy.b
Importance of adherence to diet and exercise regimen.a b
Risk of photosensitivity reactions.a b
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs.b
Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.b Inform patients that tolazamide is not recommended during pregnancy.b
Importance of informing patients of other important precautionary information.b (See Cautions.)
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer |
|---|---|---|---|---|
Oral | Tablets | 250 mg* | Tolazamide Tablets (scored) | |
500 mg* | Tolazamide Tablets (scored) |
This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 03/2011. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.
TOLAZamide 100MG Tablets (IVAX PHARMACEUTICALS INC.): 60/$26.99 or 180/$68.97
TOLAZamide 250MG Tablets (MYLAN): 60/$35.99 or 180/$96.97
TOLAZamide 500MG Tablets (MYLAN): 30/$45.99 or 90/$109.96
This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.
The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.
AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions May 2009. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.
101. The Upjohn Company. Micronase (glyburide) prescribing information. Kalamazoo, MI; 1988 May.
102. Hoechst-Roussel Pharmaceuticals Inc. Diaβeta (glyburide) prescribing information. Somerville, NJ; 1987 Dec.
103. Anon. Glibenclamide: a review. Drugs. 1971; 1:116-40. [PubMed 5004340]
104. DeFronzo RA, Ferrannini E, Koivisto V. New concepts in the pathogenesis and treatment of noninsulin-dependent diabetes mellitus. Am J Med. 1983; 74(Suppl 1A):52-81. [IDIS 164138] [PubMed 6337486]
105. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes. 1979; 28:1039-57. [PubMed 510803]
106. Koda-Kimble MA. Diabetes mellitus. In: Koda-Kimble MA, Young LY, eds. Applied therapeutics: the clinical use of drugs. 5th ed. Vancouver, WA: Applied Therapeutics, Inc.; 1992:72–1-53.
107. Skyler JS. Non-insulin-dependent diabetes mellitus: a clinical strategy. Diabetes Care. 1984; 7(Suppl 1):118-29. [PubMed 6376024]
108. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352:837-53. [IDIS 413216] [PubMed 9742976]
109. American Diabetes Association. Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care. 1999; 22(Suppl 1):27-31. [IDIS 437591] [PubMed 10333899]
110. Matthews DR, Cull CA, Stratton RR et al. UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over 6 years. Diabet Med. 1998; 15:297-303. [PubMed 9585394]
111. Genuth P. United Kingdom prospective diabetes study results are in. J Fam Pract. 1998; 47:(Suppl 5):S27.
112. Bretzel RG, Voit K, Schatz H et al. The United Kingdom Prospective Diabetes Study (UKPDS): implications for the pharmacotherapy of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 1998; 106:369-72. [PubMed 9831300]
113. Schmitt JK, Moore JR. Hypertension secondary to chlorpropamide with amelioration by changing to insulin. Am J Hypertens. 1993; 6:317-9. [PubMed 8507452]
114. Genuth S, Brownless MA, Kuller LH et al. Consensus development conference on insulin resistance: Novermber 5-6 1997. Diabetes Care. 1998; 21:310-4. [IDIS 400179] [PubMed 9540000]
115. Henry RR. Glucose control and insulin resistance in non-insulin-dependent diabetes mellitus. Ann Intern Med. 1996; 124:97-103. [IDIS 358776] [PubMed 8554221]
116. Lebovitz HE. Stepwise and combination drug therapy for the treatment of NIDDM. Diabetes Care. 1994; 17:1542-4. [IDIS 340102] [PubMed 7882832]
117. Nathan DM. Some answers, more controversy, from UKDS. Lancet. 1998; 352:832-3. [IDIS 413214] [PubMed 9742972]
118. Reviewers’ comments (personal observations) on metformin.
119. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2006; 29(Suppl 1):S4-42.
120. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329:977-86. [IDIS 320201] [PubMed 8366922]
121. Klein R, Klein BEK, Moss SE et al. Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. JAMA. 1988; 260:2864-71. [PubMed 3184351]
122. American Diabetes Association. Implications of the diabetes control and complications trial. Diabetes Care. 1996; 19:50-2S.
123. Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus; a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995; 28:103-17. [PubMed 7587918]
124. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metfromin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998; 352:854-65. [IDIS 413217] [PubMed 9742977]
125. American Diabetes Association. The United Kingdom Prospective Diabetes Study (UKPDS) for type 2 diabetes: what you need to know about the results of a long-term study. Washington, DC; September 15, 1998. From American Diabetes Association web site.
126. Davis TM. United Kingdom Prospective Diabetes Study: the end of the beginning? Med J Aust. 1998; 169:511-2.
127. Watkins PJ. UKPDS: a message of hope and a need for change. Diabet Med. 1998; 15:895-6. [PubMed 9827842]
128. Turner RC, Cull CA, Frighi V et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirements for multiple therapies (UKPDS 49). JAMA. 1999; 281:2005-12. [IDIS 425712] [PubMed 10359389]
129. Scientific Advisory Panel of the Executive Committee, American Diabetes Association. Policy statement: the UGDP controversy. Diabetes. 1979; 28:168-70.
130. Jackson JE, Bressler R. Clinical pharmacology of sulphonylurea hypoglycaemic agents: part 2. Drugs. 1981; 22:295-320. [IDIS 143257] [PubMed 7030708]
131. Food and Drug Administration. Labeling for oral hypoglycemic drugs of the sulfonylurea class. [Docket No. 75N-0062] Fed Regist. 1984; 49:14303-31.
132. Pharmacia & Upjohn Company. Tolinase (tolazamide) tablets prescribing information. Kalamazoo, MI; 2000 Jan.
133. American Diabetes Association. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2000; 23(Suppl 1):S4-19.
134. American Diabetes Association. Type 2 diabetes in children and adolescents. Pediatrics. 2000; 105:671-80. [IDIS 443594] [PubMed 10699131]
135. American Diabetes Association. Office guide to diagnosis and classification of diabetes mellitus and other categories of glucose intolerance. Diabetes Care. 1995; 18(Suppl 1):4.
136. Williams G. Management of non-insulin-dependent diabetes mellitus. Lancet. 1994; 343:95-100. [IDIS 324190] [PubMed 7903785]
137. Genuth S. Exogenous insulin administration and cardiovascular risk in non-insulin-dependent and insulin-dependent diabetes mellitus. Ann Intern Med. 1996;124(1 Part 2):104-9.
138. DeFronzo RA. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes. 1988; 37:667-87. [PubMed 3289989]
139. Polonsky KS, Sturis J, Bell GI. Non-insulin-dependent diabetes mellitus-a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med. 1996; 334:777-83. [PubMed 8592553]
140. Swislocki A. Insulin resistance and hypertension. Am J Med Sci. 1990; 300:104-15. [IDIS 272104] [PubMed 2206054]
141. United Kingdom Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998; 317:703-13. [IDIS 412064] [PubMed 9732337]
142. UK Prospective Diabetes Study (UKPDS) Group. Efficacy of atenolol and captopril in reducing risk of macrovascular complications in type 2 diabetes mellitus: UKPDS 39. BMJ. 1998; 317:713-20. [IDIS 412065] [PubMed 9732338]
143. Haffner SM, Hanefeld M, Fischer S et al. Glibenclamide, but not acarbose, increase leptin concentrations parallel to changes in insulin in subjects with NIDDM. Diabetes Care. 1997; 20: 1430-4. [IDIS 393377] [PubMed 9283792]
144. Shi H, Moustaid-Moussa N, Wilkison WO et al. Role of the sulfonylurea receptor in regulating human adipocyte metabolism. FASEB J. 1999; 13:1833-8. [PubMed 10506587]
145. Cheskin LJ, Bartlett SJ, Zayas R et al. Prescription medications: a modifiable contributor to obesity. South Med J. 1999; 92:898-904. [IDIS 435069] [PubMed 10498166]
146. Chow CC, Sorensen JP, Tsang LWW et al. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients. Diabetes Care. 1995; 18:307-14. [IDIS 346283] [PubMed 7555472]
147. Zimmerman B, Espenshade J, Fujimoto W et al. The pharmacological treatment of hyperglycemia in NIDDM. Diabetes Care. 1996; 19:1510-18.
148. Expert Committee of the Canadian Diabetes Advisory Board. Clinical practice guidelines for treatment of diabetes mellitus. Can Med Assoc J. 1992; 147:697-712.
149. Raskin P. Combination therapy in NIDDM N Engl J Med. 1992; 327:1453-4. Editorial.
150. Pugh JA, Ramirez G, Wagner ML et al. Is combination sulfonylurea and insulin therapy useful in NIDDM patients? A metaanalysis. Diabetes Care. 1992; 15:953-9. [PubMed 1387073]
151. Landstedt-Hallin L, Bolinder J, Adamson U et al. Comparison of bedtime NPH or preprandial regular insulin combined with glibenclamide in secondary sulfonylurea failure. Diabetes Care. 1995; 18:1183-6. [IDIS 351422] [PubMed 7587856]
152. Trischitta V, Italia S, Mazzarino S et al. Comparison of combined therapies in treatment of secon dary failure to glyburide. Diabetes Care. 1992; 15:539-42. [PubMed 1499473]
153. Krentz AJ, Ferner RE, Bailey CJ. Comparative tolerability profiles of oral antidiabetic agents. Drug Safety. 1994; 11:223-41. [PubMed 7848543]
154. Buse J. Combining insulin and oral agents. Am J Med. 2000; 108(Suppl 6A):23S-32S. [IDIS 446200] [PubMed 10764847]
155. Johnson JL, Wolf SL, Kabadi UM. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes: a meta-analysis of the randomized placebo-controlled trials. Arch Intern Med. 1996; 156:259-64. [IDIS 363130] [PubMed 8572835]
156. Florence JA, Yeager BF. Treatment of type 2 diabetes mellitus. Am Fam Physician. 1999; 59:2835-44. [IDIS 428714] [PubMed 10348076]
157. Yki-Jarvinen H, Dressler A, Ziemen M et al. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime HPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care. 2000; 23:1130-6 (IDIS 451244) [IDIS 451244] [PubMed 10937510]
158. Bastyr EJ, Johnson ME, Trautman ME et al. Insulin lispro in the treatment of patients with type 2 diabetes mellitus after oral agent failure. Clin Ther. 1999; 21:1703-4. [IDIS 438022] [PubMed 10566566]
159. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999; 131:281-303. [IDIS 430576] [PubMed 10454950]
160. Lebovitz HE. Clinical utility of oral hypoglycemic agents in the management of patients with noninsulin-dependent diabetes mellitus. Am J Med. 1983; 75(Suppl. 5B):94-9.
161. Anon. Diabetes mellitus. NIH Cons Dev Conf Statement. 1986; 6:1-7.
162. Blake GH. Control of type II diabetes: reaping the rewards of exercise and weight loss. Postgrad Med. 1992; 92:129-32. [PubMed 1437899]
163. Kerr CP. Improving outcomes in diabetes: a review of the outpatient care of NIDDM patients. J Fam Pract. 1995; 40:63-75. [PubMed 7807040]
164. Bailey C, Turner R. Metformin. N Engl J Med. 1996; 334:574-9. [IDIS 360526] [PubMed 8569826]
165. Turner R, Cull C, Holman R et al. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med. 1996; 124(1 Pt 2):136-45. [IDIS 358782] [PubMed 8554206]
166. Bristol-Myers-Squibb Company. Glucovance(glyburide and metformin hydrochloride) tablets prescribing information. Princeton, NJ; 2002 Oct.
167. Pfizer Inc. Glucotrol XL(glipizide) extended release tablets prescribing information. New York, NY; 2001 Apr.
168. Pfizer. Diflucan (fluconazole) tablets, for oral suspension, and injection prescribing information. New York, NY; 1998 Jun.
169. Wolffenbuttel BHR, Gomist R, Squatrito S et al. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabet Med. 2000; 17:40-7. [PubMed 10691158]
170. Takeda Pharmaceuticals America. Actos (pioglitazone hydrochloride) tablets prescribing information. Lincolnshire, IL; 2002 July.
171. SmithKline Beecham. Avandia (rosiglitazone maleate) tablets prescribing information. Philadelphia, PA; 2002 May
172. Kipnes MS, Krosnick a, Rendell MS et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med. 2001; 111:10-7. [IDIS 467740] [PubMed 11448655]
173. Chiasson J, Josse R, Hunt J et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. Ann Intern Med. 1994; 121:929-935.
174. Coniff RF, Shapiro JA, Seaton TB et al. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. Am J Med. 1995; 98:443-51. [IDIS 348267] [PubMed 7733122]
175. Calle-Pascual AL, Garcia-Honduvilla J, Martin-Alvarez PJ et al. Comparison between acarbose, metformin, and insulin treatment in type 2 diabetic patients with secondary failure to sulfonylurea treatment. Diabetes Metab. 1995; 21:256-60.
176. Klein W. S
Generic Name: coal tar (Topical route)
kole tar
In the U.S.
In Canada
Available Dosage Forms:
Therapeutic Class: Keratolytic
Coal tar is used to treat eczema, psoriasis, seborrheic dermatitis, and other skin disorders.
Some of these preparations are available only with your doctor's prescription.
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:
Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Coal tar products should not be used on infants, unless otherwise directed by your doctor. Studies on this medicine have been done only in adult patients, and there is no specific information comparing use of this medicine in children with use in other age groups.
Many medicines have not been studied specifically in older people. Therefore, it may not be known whether they work exactly the same way they do in younger adults or if they cause different side effects or problems in older people. There is no specific information comparing use of this medicine in the elderly with use in other age groups.
Studies in women suggest that this medication poses minimal risk to the infant when used during breastfeeding.
Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. Tell your healthcare professional if you are taking any other prescription or nonprescription (over-the-counter [OTC]) medicine.
Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.
This section provides information on the proper use of a number of products that contain coal tar. It may not be specific to Tar Distillate. Please read with care.
Use this medicine only as directed. Do not use more of it and do not use it more often than recommended on the label, unless otherwise directed by your doctor. To do so may increase the chance of side effects.
After applying coal tar, protect the treated area from direct sunlight and do not use a sunlamp for 72 hours, unless otherwise directed by your doctor, since a severe reaction may occur. Also, make sure you have removed all the coal tar medicine from your skin before you go back into direct sunlight or use a sunlamp.
Do not apply this medicine to infected, blistered, raw, or oozing areas of the skin.
Keep this medicine away from the eyes. If you should accidentally get some in your eyes, flush them thoroughly with water at once.
To use the cream or ointment form of this medicine:
To use the gel form of this medicine:
To use the shampoo form of this medicine:
To use the nonshampoo liquid form of this medicine:
The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.
The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.
If you miss a dose of this medicine, apply it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule.
Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.
Keep out of the reach of children.
Do not keep outdated medicine or medicine no longer needed.
If this medicine is used on the scalp, it may temporarily discolor blond, bleached, or tinted hair.
Coal tar may stain the skin or clothing. Avoid getting it on your clothing. The stain on the skin will wear off after you stop using the medicine.
In animal studies, coal tar has been shown to increase the chance of skin cancer.
Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor as soon as possible if any of the following side effects occur:
Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
See also: Tar Distillate Topical side effects (in more detail)
The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.
The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.
Generic Name: prenatal multivitamins (PRE nay tal VYE ta mins)
Brand Names: Advance Care Plus, Bright Beginnings, Cavan Folate, Cavan One, Cavan-Heme OB, Cenogen Ultra, CitraNatal Rx, Co Natal FA, Complete Natal DHA, Complete-RF, CompleteNate, Concept OB, Docosavit, Dualvit OB, Duet, Edge OB, Elite OB 400, Femecal OB, Folbecal, Folcaps Care One, Folivan-OB, Foltabs, Gesticare, Icar Prenatal, Icare Prenatal Rx, Inatal Advance, Infanate DHA, Kolnatal DHA, Lactocal-F, Marnatal-F, Maternity, Maxinate, Mission Prenatal, Multi-Nate 30, Multinatal Plus, Nata 29 Prenatal, Natachew, Natafort, Natelle, Neevo, Nestabs, Nexa Select with DHA, Novanatal, NovaStart, O-Cal Prenatal, OB Complete, OB Natal One, Ob-20, Obtrex DHA, OptiNate, Paire OB Plus DHA, PNV Select, PNV-Total, PR Natal 400, Pre-H-Cal, Precare, PreferaOB, Premesis Rx, PrenaCare, PrenaFirst, PrenaPlus, Prenatabs OBN, Prenatabs Rx, Prenatal 1 Plus 1, Prenatal Elite, Prenatal Multivitamins, Prenatal Plus, Prenatal S, Prenatal-U, Prenate Advanced Formula, Prenate DHA, Prenate Elite, Prenavite FC, PreNexa, PreQue 10, Previte Rx, PrimaCare, Pruet DHA, RE OB Plus DHA, Renate, RightStep, Rovin-NV, Se-Care, Se-Natal One, Se-Plete DHA, Se-Tan DHA, Select-OB, Seton ET, Strongstart, Stuart Prenatal with Beta Carotene, Tandem OB, Taron-BC, Tri Rx, TriAdvance, TriCare, Trimesis Rx, Trinate, Triveen-PRx RNF, UltimateCare Advance, Ultra-Natal, Vemavite PRX 2, VeNatal FA, Verotin-BY, Verotin-GR, Vinacal OR, Vinatal Forte, Vinate Advanced (New Formula), Vinate AZ, Vinate Care, Vinate Good Start, Vinate II (New Formula), Vinate III, Vinate One, Vitafol-OB, VitaNatal OB plus DHA, Vitaphil, Vitaphil Aide, Vitaphil Plus DHA, Vitaspire, Viva DHA, Vol-Nate, Vol-Plus, Vol-Tab Rx, Vynatal F.A., Zatean-CH, Zatean-PN
There are many brands and forms of prenatal vitamin available and not all brands are listed on this leaflet.
Prenatal vitamins are a combination of many different vitamins that are normally found in foods and other natural sources.
Prenatal vitamins are used to provide the additional vitamins needed during pregnancy. Minerals may also be contained in prenatal multivitamins.
Prenatal vitamins may also be used for purposes not listed in this medication guide.
There are many brands and forms of prenatal vitamin available and not all brands are listed on this leaflet.
Many multivitamin products also contain minerals such as calcium, iron, magnesium, potassium, and zinc. Minerals (especially taken in large doses) can cause side effects such as tooth staining, increased urination, stomach bleeding, uneven heart rate, confusion, and muscle weakness or limp feeling. Read the label of any multivitamin product you take to make sure you are aware of what it contains.
Overdose symptoms may include stomach pain, vomiting, diarrhea, constipation, loss of appetite, hair loss, peeling skin, tingly feeling in or around your mouth, changes in menstrual periods, weight loss, severe headache, muscle or joint pain, severe back pain, blood in your urine, pale skin, and easy bruising or bleeding.
Before taking prenatal vitamins, tell your doctor about all of your medical conditions.
Use exactly as directed on the label, or as prescribed by your doctor. Do not use in larger or smaller amounts or for longer than recommended.
Many multivitamin products also contain minerals such as calcium, iron, magnesium, potassium, and zinc. Minerals (especially taken in large doses) can cause side effects such as tooth staining, increased urination, stomach bleeding, uneven heart rate, confusion, and muscle weakness or limp feeling. Read the label of any multivitamin product you take to make sure you are aware of what it contains.
Swallow the regular tablet or capsule whole. Do not break, chew, crush, or open it.
The chewable tablet must be chewed or allowed to dissolve in your mouth before swallowing. You may also allow the chewable tablet to dissolve in drinking water, fruit juice, or infant formula (but not milk or other dairy products). Drink this mixture right away.
Use prenatal vitamins regularly to get the most benefit. Get your prescription refilled before you run out of medicine completely.
Take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.
Overdose symptoms may include stomach pain, vomiting, diarrhea, constipation, loss of appetite, hair loss, peeling skin, tingly feeling in or around your mouth, changes in menstrual periods, weight loss, severe headache, muscle or joint pain, severe back pain, blood in your urine, pale skin, and easy bruising or bleeding.
Avoid the regular use of salt substitutes in your diet if your multivitamin contains potassium. If you are on a low-salt diet, ask your doctor before taking a vitamin or mineral supplement.
When taken as directed, prenatal vitamins are not expected to cause serious side effects. Less serious side effects may include:
upset stomach;
headache; or
unusual or unpleasant taste in your mouth.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Vitamin and mineral supplements can interact with certain medications, or affect how medications work in your body. Before taking a prenatal vitamin, tell your doctor if you also use:
diuretics (water pills);
heart or blood pressure medications;
tretinoin (Vesanoid);
isotretinoin (Accutane, Amnesteen, Clavaris, Sotret);
trimethoprim and sulfamethoxazole (Cotrim, Bactrim, Gantanol, Gantrisin, Septra, TMP/SMX); or
an NSAID (non-steroidal anti-inflammatory drug) such as ibuprofen (Advil, Motrin), naproxen (Aleve, Naprosyn, Naprelan, Treximet), celecoxib (Celebrex), diclofenac (Cataflam, Voltaren), indomethacin (Indocin), meloxicam (Mobic), and others.
This list is not complete and other drugs may interact with prenatal vitamins. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.
